UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Anti-PCSK9 Monotherapy for Hypercholesterolemia: The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab

Journal of the American College of Cardiology, 2014-06, Vol.63 (23), p.2531-2540

2014

Volltextzugriff (PDF)

Hypertension Management: Rationale for Triple Therapy Based on Mechanisms of Action

Cardiovascular therapeutics, 2013-10, Vol.31 (5), p.251-258

2013

Volltextzugriff (PDF)

Anti-PCSK9 Monotherapy for Hypercholesterolemia

Journal of the American College of Cardiology, 2014-06, Vol.63 (23), p.2531-2540

2014

Volltextzugriff (PDF)

98-OR: Oral Insulin Alleviates Liver Fibrosis and Reduces Fat in Patients with NASH and Type 2 Diabetes—Results of Phase II Clinical Trial

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial

JAMA : the journal of the American Medical Association, 2014-05, Vol.311 (18), p.1870

2014

Volltextzugriff (PDF)

Clinical studies of CS-866, the newest angiotensin II receptor antagonist

The American journal of cardiology, 2001-04, Vol.87 (8), p.37-43

Neutel, Joel M

2001

Volltextzugriff (PDF)

Management of Hypertension in Patients With Diabetes Using an Amlodipine-, Olmesartan Medoxomil-, and Hydrochlorothiazide-Based Titration Regimen

The American journal of cardiology, 2011-05, Vol.107 (9), p.1346-1352

2011

Volltextzugriff (PDF)

Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID‐19

Journal of clinical pharmacology, 2024-02, Vol.64 (2), p.145-154

2024

Volltextzugriff (PDF)

First-in-Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe Disease

Clinical pharmacology and therapeutics, 2024-10

2024

Volltextzugriff (PDF)

Single-Pill Combination of Telmisartan/Amlodipine Versus Amlodipine Monotherapy in Diabetic Hypertensive Patients: An 8-Week Randomized, Parallel-Group, Double-Blind Trial

Clinical therapeutics, 2012-03, Vol.34 (3), p.537-551

2012

Volltextzugriff (PDF)

41-LB: A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of a Natural Powder Blend (Mulberry Leaf Extract [MLE], Vitamin D, Chromium, and Fiber) on Postprandial (PP) Metabolic Response in Type 2 Diabetes (T2D)

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study

Journal of the American Society of Hypertension, 2014-12, Vol.8 (12), p.915-920

2014

Volltextzugriff (PDF)

Contrasting clinical properties and exercise responses in obese and lean hypertensive patients

Journal of the American College of Cardiology, 2001-01, Vol.37 (1), p.169-174

2001

Volltextzugriff (PDF)

Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: Pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials

Clinical therapeutics, 2005-11, Vol.27 (11), p.1795-1805

2005

Volltextzugriff (PDF)

Telmisartan/Hydrochlorothiazide in Comparison with Losartan/Hydrochlorothiazide in Managing Patients with Mild-to-Moderate Hypertension

Hypertension research, 2005-07, Vol.28 (7), p.555-563

2005

Volltextzugriff (PDF)

The Use of a Single‐Pill Calcium Channel Blocker/Statin Combination in the Management of Hypertension and Dyslipidemia: A Randomized, Placebo‐Controlled, Multicenter Study

The journal of clinical hypertension (Greenwich, Conn.), 2009-01, Vol.11 (1), p.22-30

2009

Volltextzugriff (PDF)

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures

Diabetes therapy, 2013-12, Vol.4 (2), p.269-283

2013

Volltextzugriff (PDF)

Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients

Current medical research and opinion, 2008-08, Vol.24 (8), p.2389-2401

Neutel, Joel M.

2008

Volltextzugriff (PDF)

37-LB: Very-Low-Dose Premeal Whey Protein Microgels Reduce Postprandial (PP) Glucose in Type 2 Diabetes: A Randomized, Placebo-Controlled Crossover Study

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Comparison of long‐term safety of fixed‐dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide

The journal of clinical hypertension (Greenwich, Conn.), 2017-09, Vol.19 (9), p.874-883

2017

Volltextzugriff (PDF)

A prospective, randomized, open label, 4 way crossover study to assess the bioavailability of valsartan er 160 mg dosed following a high fat, medium fat, and after an 8 hour fast compared to diovan 160 mg dosed following an 8 hour fast

Journal of the American Society of Hypertension, 2015-04, Vol.9 (4), p.e23-e23

Neutel, Joel M

2015

Volltextzugriff (PDF)

A prospective, randomized, open label, blinded end point, crossover study comparing valsartan ER to diovan in stage I and stage II hypertensive patients

Journal of the American Society of Hypertension, 2015-04, Vol.9 (4), p.e22-e23

Neutel, Joel M

2015

Volltextzugriff (PDF)

The role of combination therapy in the management of hypertension

Nephrology, dialysis, transplantation, 2006-06, Vol.21 (6), p.1469-1473

NEUTEL, Joel M

2006

Volltextzugriff (PDF)

Telmisartan in combination with hydrochlorothiazide 12.5 mg for the management of patients with hypertension

Current medical research and opinion, 2014-09, Vol.30 (9), p.1715-1724

2014

Volltextzugriff (PDF)

Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process

American journal of hypertension, 2004-12, Vol.17 (12 Pt 2), p.23S-30S

2004

Volltextzugriff (PDF)

1 – 25 von 256

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(234)
Mit Volltextzugriff
(218)

Publikationsform

Sprache

Englisch
(255)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(148)
Life Sciences & Biomedicine
(120)
Science & Technology
(120)
Hypertension - Drug Therapy
(110)
Male
(102)
Female
(99)
Middle Aged
(94)
Cardiovascular System & Cardiology
(78)
Aged
(70)
Antihypertensive Agents - Therapeutic Use
(64)
Biological And Medical Sciences
(63)
Medical Sciences
(62)
Adult
(60)
Blood Pressure - Drug Effects
(60)
Hypertension
(58)
Drug Therapy, Combination
(55)
Hypertension - Physiopathology
(50)
Peripheral Vascular Disease
(50)
Treatment Outcome
(47)
Antihypertensive Agents - Administration & Dosage
(42)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Anti-PCSK9 Monotherapy for Hypercholesterolemia: The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab

Hypertension Management: Rationale for Triple Therapy Based on Mechanisms of Action

Anti-PCSK9 Monotherapy for Hypercholesterolemia

98-OR: Oral Insulin Alleviates Liver Fibrosis and Reduces Fat in Patients with NASH and Type 2 Diabetes—Results of Phase II Clinical Trial

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial

Clinical studies of CS-866, the newest angiotensin II receptor antagonist

Management of Hypertension in Patients With Diabetes Using an Amlodipine-, Olmesartan Medoxomil-, and Hydrochlorothiazide-Based Titration Regimen

Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID‐19

First-in-Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe Disease

Single-Pill Combination of Telmisartan/Amlodipine Versus Amlodipine Monotherapy in Diabetic Hypertensive Patients: An 8-Week Randomized, Parallel-Group, Double-Blind Trial

41-LB: A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of a Natural Powder Blend (Mulberry Leaf Extract [MLE], Vitamin D, Chromium, and Fiber) on Postprandial (PP) Metabolic Response in Type 2 Diabetes (T2D)

Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study

Contrasting clinical properties and exercise responses in obese and lean hypertensive patients

Telmisartan/Hydrochlorothiazide in Comparison with Losartan/Hydrochlorothiazide in Managing Patients with Mild-to-Moderate Hypertension

The Use of a Single‐Pill Calcium Channel Blocker/Statin Combination in the Management of Hypertension and Dyslipidemia: A Randomized, Placebo‐Controlled, Multicenter Study

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures

Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients

37-LB: Very-Low-Dose Premeal Whey Protein Microgels Reduce Postprandial (PP) Glucose in Type 2 Diabetes: A Randomized, Placebo-Controlled Crossover Study

Comparison of long‐term safety of fixed‐dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide

A prospective, randomized, open label, 4 way crossover study to assess the bioavailability of valsartan er 160 mg dosed following a high fat, medium fat, and after an 8 hour fast compared to diovan 160 mg dosed following an 8 hour fast

A prospective, randomized, open label, blinded end point, crossover study comparing valsartan ER to diovan in stage I and stage II hypertensive patients

The role of combination therapy in the management of hypertension

Telmisartan in combination with hydrochlorothiazide 12.5 mg for the management of patients with hypertension

Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process

Suchergebnisse filtern